Peter Lothes Is Appointed Global COO at Advancing Eyecare

Peter Lothes will oversee all operations of Advancing Eyecare’s industry-leading ophthalmic equipment businesses, including Lombart Instrument, Marco Ophthalmic, INNOVA Medical, and Santinelli International.

Peter Lothes joins Advancing Eyecare with over 30 years of global leadership experience in vision care, including manufacturing, supply chain, and global operations. Most recently, he served as Senior Vice President, Operations and Supply Chain at EssilorLuxottica of America. Over the years, he held many positions throughout the EssilorLuxottica group, including President and Global CEO of Satisloh Worldwide, President and CEO of Satisloh North America, and Vice President of Operations – Production Labs of Essilor of America.

A graduate of Ashland University with a degree in Business Management and a Minor in Marketing, prior to EssilorLuxottica, Peter Lothes was president of his family business, Select Optical – which was acquired by Essilor in 2004 and became part of the Partner Lab Family – for over 17 years.

Brad Staley, Chief Executive Officer of Advancing Eyecare, said, “We are excited to welcome Pete to the Advancing Eyecare family. With his high-integrity leadership, deep industry experience, and extensive track record in developing innovative business strategies to drive growth on a global scale, he is uniquely positioned to help AEC continue to evolve and bring new and innovative solutions to eye care practitioners around the world.”

“I am incredibly excited to be a part of the Advancing Eyecare team,” said Lothes. “With Advancing Eyecare’s best-in-class companies, superior reputation, and customer-centric technology and service solutions to help improve vision, the groundwork has been set and the company is poised for accelerated growth in the North America as well as entry into new markets and geographies. I look forward to being a part of AEC’s bright future.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution